Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2022 | Toxicities associated with ide-cel in KarMMa

Doris Hansen • 4 Jun 2022
ASCO 2022
Multiple Myeloma CAR-T Idecabtagene vicleucel
KarMMa

Doris K. Hansen, MD, Moffitt Cancer Center, Tampa, FL, reflects on toxicities associated with idecabtagene vicleucel (ide-cel) in multiple myeloma including neurotoxicity, cytokine release syndrome (CRS) and cytopenias. Dr Hansen highlights strategies employed to mitigate the incidence of treatment-related adverse events. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Doris Hansen

Strategies being explored to optimize CAR T-cell therapy for high-risk multiple myeloma 1:07
Strategies being explored to optimize CAR T-cell therapy for high-risk multiple myeloma
Doris Hansen • 23 Oct 2025
What is considered an “optimal” response when treating a patient with myeloma with CAR-T? 0:53
What is considered an “optimal” response when treating a patient with myeloma with CAR-T?
Doris Hansen • 23 Oct 2025
The potential of CAR-T to improve the outcomes of patients with high-risk myeloma 1:43
The potential of CAR-T to improve the outcomes of patients with high-risk myeloma
Doris Hansen • 23 Oct 2025
Optimizing bridging therapy prior to CAR T-cell therapy in multiple myeloma 1:09
Optimizing bridging therapy prior to CAR T-cell therapy in multiple myeloma
Doris Hansen • 20 Sep 2025

Related Videos

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals